Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Johnson & Johnson
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment
Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...
Johnson & Johnson’s Darzalex Faspro Showcases Clinical Efficacy in Multiple Myeloma at ASH 2024
US healthcare conglomerate Johnson & Johnson (J&J, NYSE: JNJ) has presented results from several clinical...
Tecvayli (Teclistamab) Demonstrates Positive Results in MajesTEC-5 and MajesTEC-4 Trials
Janssen-Cilag International NV, a subsidiary of US healthcare giant Johnson & Johnson (J&J; NYSE: JNJ),...
Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...
Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis
Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis
Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...
Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...
Janssen-Cilag’s Nipocalimab Shows Promise in Phase II Study for Sjögren’s Disease
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), has unveiled the...
Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...
J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials
US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...
J&J’s Nipocalimab Receives FDA Breakthrough Therapy Designation for Sjögren’s Disease
US-based pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received...
J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab
Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...
Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment
Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...
Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment
US major Johnson & Johnson (J&J, NYSE: JNJ) MedTech has announced the completion of pilot...
Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC
Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s...
Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...